- 3-2-1 Health Tech
- Posts
- 3-2-1 Blindness and Vision Loss
3-2-1 Blindness and Vision Loss
Priyanka Vaidya
June 02, 2025
Blindness and vision loss refer to significant reductions in a person’s ability to see, which cannot be fully corrected with standard glasses, contact lenses, medication, or surgery. These conditions are a major global public health challenge, affecting quality of life, economic productivity, and social inclusion.
The leading causes of blindness and near vision impairment globally are cataracts, which occur when the eye’s lens becomes cloudy, resulting in blurred or dim vision. Cataracts are especially prevalent in older adults but can affect people of all ages. Uncorrected Refractive Errors include conditions like myopia (nearsightedness), hyperopia (farsightedness), and astigmatism. Uncorrected refractive errors are the largest contributor to moderate and severe vision impairment and a significant cause of blindness when left untreated. Glaucoma is a group of eye diseases that damages the optic nerve and is the leading cause of irreversible blindness. Glaucoma often progresses without symptoms until significant vision loss has occurred. Age-Related Macular Degeneration (AMD) affects the central part of the retina, leading to loss of central vision, and is a major cause of vision impairment in older adults, particularly in high-income countries. Diabetic Retinopathy is caused by damage to the blood vessels in the retina due to diabetes, diabetic retinopathy is a growing cause of vision loss globally as diabetes becomes more prevalent.
3 startups making an impact in this space:
Company | |||
Location | US | Romania | Finland |
Modality | Diagnostics | Care access | Therapeutics |
Descriptor | Deep-learning AI technology that ensures the fastest and most accurate assessments for diabetic retinopathy. | Pedestrian autonomous driving AI - glasses for the blind. | Curing blindness through regenerative stem cell therapies. |
Core Problem | Early detection is key to saving vision in case of diabetic retinopathy. But screening is limited and complex. | There are 338 million visually impaired people and 28 thousand guide dogs. | Corneal blindness is a global problem affecting over 12 million people, and there is a severe shortage of donors. |
Solution | Patients with vision-threatening retinopathy can be identified in the clinic in real-time by providers using Nsight360, so they can be referred to an eye specialist to save their vision. | .lumen has created glasses that replicate the main features of a guide dog. | Stemsight’s aim is to address the significant shortage of corneal tissue transplants by creating off-the-shelf spare parts for the cornea that do not rely on donor tissue. |
Product Suite | Nsight360 combines the power of AI with the expertise of ophthalmologists to provide rapid and accurate diagnoses. | Patented haptic interface powers the .lumen glasses, which function like a guide dog. | Functional biomaterials and iPS-derived cells are combined to accelerate tissue regeneration. |
Regulatory Status | FDA-cleared. | In process | In process |
Funding Stage | — | Series B | Seed |
Team | Co-founders are physician entrepreneurs and AI experts. | Team of 50 researchers, engineers, and designers. | Team of scientists and business professionals. |
Traction | Early traction. | Promising early traction and innovation awards. | Promising early traction and innovation awards. |
2 actionable insights to inspire your strategy.
Artificial Intelligence Artificial intelligence is transforming the early detection of eye diseases such as glaucoma, diabetic retinopathy, and macular degeneration. AI systems analyze retinal images with high precision, often identifying subtle changes before symptoms appear, enabling earlier and more effective interventions. AI-powered smart glasses and real-time vision assistance devices help people with vision loss navigate their environment, read text, and recognize faces. These tools are becoming more accurate and responsive, enhancing daily independence. | Gene and Stem Cell therapies Gene-editing approaches are being developed to repair or replace faulty genes responsible for inherited retinal diseases. Early-stage clinical trials have shown promise in restoring partial vision or slowing disease progression in patients with genetic forms of blindness. Advances in tissue engineering and regenerative medicine, such as 3D-printed corneas and stem cell-based treatments, are expanding options for restoring vision in patients with corneal blindness. |
1 key resource to deepen your understanding.
To hear more about the experiences of people who have been blind from birth (what do they dream about?) and other visually impaired people sharing stories, take a listen to this episode from the podcast ‘Life after Blindness’:
And that’s all for today. See you next Monday!
Would love to hear your feedback. If you like the newsletter, please share it with your friends and colleagues!